19614786

Source:http://linkedlifedata.com/resource/pubmed/id/19614786

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0008976, umls-concept:C0011860, umls-concept:C0030705, umls-concept:C0038766, umls-concept:C0178602, umls-concept:C0332161, umls-concept:C0332307, umls-concept:C1524062, umls-concept:C1611934, umls-concept:C1707455, umls-concept:C2587213
pubmed:issue	9
pubmed:dateCreated	2009-8-20
pubmed:databankReference	http://linkedlifedata.com/resource/pubmed/xref/ClinicalTrials.gov/NCT00313313
pubmed:abstractText	Assess the efficacy and safety of saxagliptin added to a submaximal sulphonylurea dose vs. uptitration of sulphonylurea monotherapy in patients with type 2 diabetes and inadequate glycaemic control with sulphonylurea monotherapy.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-10230643, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-10359389, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-10480510, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-11289482, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-12502499, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-14757293, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-15162895, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-15220224, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-15224207, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-15483097, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-15669880, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-16033281, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-16236086, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-16306327, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-16368054, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-16802130, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-17073841, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-17145742, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-17613449, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-17622601, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-17645555, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-17889380, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-18165335, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-18175761, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-18355324, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-18540046, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-18571471, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-18945920, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-19515181, http://linkedlifedata.com/resource/pubmed/commentcorrection/19614786-9742976
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9712381
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Adamantane, http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose, http://linkedlifedata.com/resource/pubmed/chemical/Dipeptides, http://linkedlifedata.com/resource/pubmed/chemical/Hypoglycemic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Sulfonylurea Compounds, http://linkedlifedata.com/resource/pubmed/chemical/saxagliptin
pubmed:status	MEDLINE
pubmed:month	Sep
pubmed:issn	1742-1241
pubmed:author	pubmed-author:ApanovitchAA, pubmed-author:CV181-040 Investigators, pubmed-author:ChacraA RAR, pubmed-author:ChenRR, pubmed-author:ListJJ, pubmed-author:RavichandranSS, pubmed-author:SawF AFA
pubmed:issnType	Electronic
pubmed:volume	63
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1395-406
pubmed:dateRevised	2011-3-24
pubmed:meshHeading	pubmed-meshheading:19614786-Adamantane, pubmed-meshheading:19614786-Adolescent, pubmed-meshheading:19614786-Adult, pubmed-meshheading:19614786-Aged, pubmed-meshheading:19614786-Analysis of Variance, pubmed-meshheading:19614786-Blood Glucose, pubmed-meshheading:19614786-Diabetes Mellitus, Type 2, pubmed-meshheading:19614786-Dipeptides, pubmed-meshheading:19614786-Double-Blind Method, pubmed-meshheading:19614786-Drug Therapy, Combination, pubmed-meshheading:19614786-Humans, pubmed-meshheading:19614786-Hypoglycemic Agents, pubmed-meshheading:19614786-Middle Aged, pubmed-meshheading:19614786-Sulfonylurea Compounds, pubmed-meshheading:19614786-Treatment Outcome, pubmed-meshheading:19614786-Young Adult
pubmed:year	2009
pubmed:articleTitle	Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial.
pubmed:affiliation	Diabetes Center, Federal University of São Paulo, São Paulo, Brazil.
pubmed:publicationType	Journal Article, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study